FDA accepts UroGen’s UGN-103 NDA for recurrent low-grade intermediate-risk bladder cancer

The submission seeks approval for a next-generation mitomycin formulation designed for intravesical treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, building on the same drug-delivery platform as FDA-approved Zusduri.

The US Food and Drug Administration (FDA) has accepted UroGen Pharma’s New Drug Application for UGN-103 for the treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), with a PDUFA target action date of 18 December 2026.

If approved, UGN-103 would provide a next-generation formulation using UroGen’s sustained-release RTGel technology, but the NDA acceptance represents the start of regulatory review rather than an approval.

Field	Content
Alert Type	Industry Update
Topic	Regulatory review; New Drug Application
Organisation(s)	UroGen Pharma; US Food and Drug Administration (FDA)
Affected Stakeholders	Urologists; patients with recurrent LG-IR-NMIBC; oncology and urology treatment centres
Therapy Area(s)	Urology; Oncology; Bladder cancer
Geography	United States
What Happened	The FDA has accepted UroGen Pharma’s NDA for UGN-103 for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer and assigned a PDUFA target action date of 18 December 2026. UGN-103 is an investigational intravesical formulation of mitomycin using UroGen’s RTGel sustained-release technology. The application is supported by the Phase III UTOPIA trial and relies in part on the FDA’s 505(b)(2) regulatory pathway. Acceptance means the application has entered substantive FDA review and does not constitute approval.
Why It Matters	Recurrent LG-IR-NMIBC has traditionally required repeated surgical procedures, particularly transurethral resection of bladder tumour. UGN-103 is designed to provide sustained exposure of bladder tissue to mitomycin through a non-surgical intravesical treatment, potentially providing another treatment option if the FDA determines that the application meets requirements for approval.
Supporting Context	UGN-103 is a next-generation formulation related to UroGen’s Zusduri (mitomycin) for intravesical solution, which received FDA approval in June 2025 for adults with recurrent LG-IR-NMIBC. UroGen developed UGN-103 using a different mitomycin manufacturing process intended to support its longer-term bladder cancer franchise.
Who Is Most Affected	Urologists and patients managing recurrent LG-IR-NMIBC are the principal stakeholders because an approval could add another intravesical mitomycin formulation using sustained-release technology to the US treatment pathway. UroGen is also directly affected because the review concerns a potential successor within its commercial bladder cancer portfolio.
Industry Impact	The NDA demonstrates UroGen’s effort to extend its RTGel-based bladder cancer platform beyond its existing Zusduri product. Any effect on treatment practice or the commercial market will depend on FDA approval, the final label, availability and subsequent clinical adoption.
Key Takeaway	FDA acceptance moves UGN-103 into formal regulatory review for recurrent LG-IR-NMIBC, with a decision expected by 18 December 2026.
What to Watch	The 18 December 2026 PDUFA target action date, the final FDA decision and, if approved, how UGN-103 is positioned relative to UroGen’s existing Zusduri treatment.
Primary Source	UroGen Pharma regulatory announcement
Relevant Date	18 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com